Cancer Center Support (CORE) Grant

描述（由申请人提供）：杰克逊实验室癌症中心（JAXCC）提供独特的遗传和基因组专业知识，专注于小鼠模型系统和系统基因组学在解决癌症问题中的应用。JAXCC有47个成员参与了一个名为“精确癌症医学遗传模型”的研究项目，该项目包括3个相关主题：癌细胞稳健性、遗传和基因组复杂性以及祖细胞生物学。总的来说，我们试图确定内在抗癌、癌症进化、适应和自我更新的分子驱动因素。基因组技术、计算分析和人类癌症小鼠模型的创新是所有主题不可或缺的一部分，提供了一个强大的跨学科结构。JAXCC现在有三个校区：JAX哺乳动物遗传学（Bar Harbor， ME），专注于复杂遗传学的小鼠模型；JAX基因组医学（法明顿，CT），专注于人类癌症基因组学；与JAX-West （Sacramento， CA）合作，专注于使用患者来源的异种移植（PDX）人类癌症小鼠模型进行临床前试验。JAX的科学领导直接监督癌症中心：刘冠文博士是JAX的总裁兼首席执行官，也是JAXCC的主任。Robert Braun博士是JAX研究副总裁兼癌症中心副主任。Drs。Carol Bult， Chengkai Dai和Frank McKeon是联合编程领导者。区域转化伙伴关系副主任（Kevin Mills博士）和研究管理副主任（Barbara Tennent博士）扩大了领导结构。一个专门的7人外部咨询委员会（EAB）为他们提供建议。新的领导班子，加上新的高级和初级研究人员的招聘，以及癌症研究机构资源的显著增加，都增强了JAXCC的影响力。这已经通过区域和国家伙伴关系（例如SWOG）在扩展的JAXCC翻译推广中实现。要求支持共享资源：a)计算科学，用于高级计算和统计分析；b)基因组技术，用于下一代测序、代谢组学和蛋白质组学分析方面的创新；c)癌症模型开发，在开发新模型时进行咨询和项目管理；d)操纵小鼠种系和体细胞基因表达的基因工程技术；e)显微镜、细胞遗传学、临床评估、组织学和流式细胞术的表型技术。还要求资金用于支持EAB年度会议和JAXCC成员务静会。需要由机构资金大量补充的发展资金，用于试点项目计划，以刺激新的癌症研究机会，并支持JAXCC的新研究人员。

DESCRIPTION (provided by applicant): The Jackson Laboratory Cancer Center (JAXCC) provides a unique concentration of genetic and genomic expertise focusing on applications of murine model systems and systems genomics in addressing cancer questions. The JAXCC has 47 members in one Research Program, Genetic Models for Precision Cancer Medicine, comprising 3 related themes in cancer cell robustness, genetic and genomic complexity, and progenitor cell biology. Collectively, we seek to determine the molecular drivers of intrinsic cancer resistance, cancer evolution, adaptation, and self-renewal. Innovations In genomic technologies, computational analytics and mouse models for human cancers are integral to all themes, providing a robust interdisciplinary structure. The JAXCC now operates on 3 campuses: JAX Mammalian Genetics (Bar Harbor, ME) with a focus on mouse models for complex genetics; JAX Genomic Medicine (Farmington, CT), with a focus on human cancer genomics; and JAX-West (Sacramento, CA) with a focus on pre-clinical trials using patient-derived-xenograft (PDX) mouse models of human cancer. The scientific leadership of JAX has direct oversight of the Cancer Center: Dr. Edison Liu is President and CEO of JAX and Director of the JAXCC. Dr. Robert Braun Is Vice President for Research of JAX and Deputy Director of the Cancer Center. Drs. Carol Bult, Chengkai Dai and Frank McKeon are co-programming Leaders. Associate Directors for Regional Translational Partnerships (Dr. Kevin Mills) and Research Administration (Dr. Barbara Tennent) expand the leadership structure. A dedicated 7-member External Advisory Board (EAB) advises them. The new leadership, combined with recruitment of new senior and junior investigators, and a significant increase in institutional resources for cancer research heightens the impact ofthe JAXCC. This has been realized In the expanded JAXCC translational outreach through regional and national partnerships (e.g., SWOG). Support is requested for Shared Resources: a) Computational Sciences, for advanced computational and statistical analysis; b) Genome Technologies, for innovations in next generation sequencing, and in metabolomic and proteomic analyses; c) Cancer Model Development for consultation and project management in developing new models; d) Genetic Engineering Technologies for manipulating germline and somatic gene expression in mice; and e) Phenotyping Technologies for microscopy, cytogenetics, clinical assessment, histology and flow cytometry. Funds are also requested for support of annual EAB meetings and JAXCC member retreats. Developmental funds significantly supplemented by institutional funds are requested for a pilot project program to stimulate new cancer research opportunities and for support of new investigators to the JAXCC.